The project adds to the 74 people already employed at the Artesyn Biosolutions facility acquired by Repligen in 2020.
Repligen Corporation is undertaking an expansion of its Waterford site which will see 130 new jobs created, Tánaiste and Minister for Enterprise, Trade and Employment Leo Varadkar, TD, has announced.
The life sciences company is building a new 3,000 sq m facility which will be a centre of excellence for single-use consumable products used in bioprocessing applications. The site currently hosts a 1,000 sq m facility employing 74 people, which was established by Ireland’s Artesyn Biosolutions before that company was acquired by Repligen last November.
Repligen Corporation is a multinational that produces bioprocessing products for use in the pharmaceutical manufacturing process. Headquartered in Massachusetts, the company has sites across the United States and in Estonia, France, Germany, Sweden and the Netherlands, as well as here in Ireland.
According to the company, the new building will be certified silver on the Leadership in Energy and Environmental Design (LEED) rating system from the US Green Building Council. The consumable products manufactured there will be used in filtration and chromatography systems during the production of vaccines and other biopharmaceutical products.
Commenting on the announcement, Varadkar said: “This is excellent news from Repligen with the creation of 130 new jobs in Waterford. It comes on foot of a major jobs announcement by Bausch and Lomb. Waterford is on the move as a centre for jobs and investment.
“I wish the team the very best with their expansion plans.”
James Bylund, senior vice-president at Repligen, added: “We are thrilled to continue the collaboration with the Irish Government and the IDA that was initiated by the Artesyn team. This build-out is an important step in expanding our capacity and establishing dual manufacturing sites for key single-use consumable products used in manufacture of biological drugs.
“With its LEED Silver designation, the facility is closely aligned with our commitment to responsible growth and sustainability.”
Dr Jonathan Downey, managing director at the Waterford facility, said: “Having delivered beyond our commitment in 2019 to bring new jobs to the region through our development of high-end manufacturing capabilities, we are energised and excited about our integration with Repligen and this next phase of growth.
“In addition to our expansion of Artesyn products, and the transfer of manufacturing of certain of Repligen’s current products to our Irish operations, we expect to be utilising the Irish sites to advance additional research, development and innovation programs.”
